Effect and Safety Study of Febuxostat in Treatment of Early,Middle and Late Stage Patients with Chronic Kidney Disease
Objective To analyze clinical effect and safety of febuxostat in early,middle,and late treatment of chronic kidney disease.Methods The paper chose 90 patients with chronic kidney disease in our hospital from 2021 to 2022,and divided them into early to mid stage group(2～3 stages,50 cases)and late stage group(4～5 stages,40 cases)based on different conditions.All cases were treated with oral febuxostat on the basis of routine treatment,levels of various observation indicators before and after treatment were observed in both groups.Results Total effective rate and incidence of adverse reactions in clinical treatment of two groups were basically similar(P>0.05),and biochemical indicators of SUA,Scr,eGFR,TC,TG,etc.between two groups were significantly better after treatment than before(P<0.05).Conclusion Febuxostat can reduce uric acid levels and protect the kidneys of patients with early,middle,and late chronic kidney disease and hyperuricemia effectively,with lower incidence of adverse reactions.
NETL
NSTL
万方数据
